6-乙酰氨基-7-氯-1,2-二氢异喹啉-1-酮 | 142678-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 6-乙酰氨基-7-氯-1,2-二氢异喹啉-1-酮
• 英文名称: 6-acetylamino-7-chloro-1,2-dihydroisoquinolin-1-one
• 英文别名: N-(7-chloro-1-oxo-1,2-dihydroisoquinolin-6-yl)acetamide；N-(7-chloro-1-oxo-2H-isoquinolin-6-yl)acetamide
• CAS: 142678-65-7
• 化学式: C₁₁H₉ClN₂O₂
• 分子量: 236.658
• InChiKey: XBWPUKKLMDHENA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-乙酰氨基-7-氯-1,2-二氢异喹啉-1-酮 在 盐酸 作用下， 以 水 为溶剂， 反应 1.0h， 生成 6-amino-7-chloro-2H-isoquinolin-1-one
  参考文献：
  名称：

  Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account

  摘要：

  Two closely related scaffolds were identified through an uHTS campaign as desirable starting points for the development of Rho-Kinase (ROCK) inhibitors. Here, we describe our hit-to-lead evaluation process which culminated in the rapid discovery of potent leads such as 22 which successfully demonstrated an early in vivo proof of concept for anti-hypertensive activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.070
• 作为产物：
  描述：

  3-acetylamino-4-chlorocinnamoylazide 在 三正丁胺 作用下， 以 二苯醚 、 正己烷 为溶剂， 生成 6-乙酰氨基-7-氯-1,2-二氢异喹啉-1-酮
  参考文献：
  名称：

  Isoquinolinone derivative

  摘要：

  该式的异喹啉酮衍生物：其中R¹为氢、C1-4烷基、C1-4烷氧基或式：-NR⁴R⁵其中R⁴为氢、卤素、C1-4烷基或C2-4烷酰基，而R⁵为氢、C1-4烷基或苄基；R²为氢或C1-4烷基；R³为氢或C1-4烷基；l为1、2、3或4；m为1或2；n为1或2；---为单键或双键。其无毒酸加合物盐和水合物具有5-HT3受体的拮抗活性，可用于预防和/或治疗5-HT作用于5-HT3受体引起的疾病（特别是由抗癌剂给药引起的呕吐）。

  公开号：

  EP0482939A1

文献信息

• RHO KINASE INHIBITORS
  申请人：Bosanac Todd

  公开号：US20080161297A1

  公开（公告）日：2008-07-03

  Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

  揭示了一种新颖的取代的2H-异喹啉-1-酮和3H-喹唑啉-4-酮衍生物，可用作Rho激酶的抑制剂，用于治疗通过Rho激酶活性介导或维持的各种疾病和疾病，包括心血管疾病，包含这些化合物的药物组合物，使用这些化合物的方法以及制备这些化合物的方法。
• Rho kinase inhibitors
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US10624882B2

  公开（公告）日：2020-04-21

  Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

  所公开的是新型取代的 2H-isoquinolin-1-one 和 3H-quinazolin-4-one 衍生物，可作为 Rho 激酶的抑制剂，用于治疗通过 Rho 激酶的活性介导或维持的各种疾病和失调，包括心血管疾病；还公开了包含此类化合物的药物组合物、使用此类化合物的方法和制造此类化合物的工艺。
• Novel 5-HT3 antagonists. Isoquinolinones and 3-aryl-2-pyridones
  作者：Toshiaki Matsui、Tsuneyuki Sugiura、Hisao Nakai、Sadahiko Iguchi、Satoshi Shigeoka、Hideo Takada、Yoshihiko Odagaki、Yuhki Nagao、Yasuyuki Ushio

  DOI：10.1021/jm00096a001

  日期：1992.9

  Synthesis and pharmacological evaluation of a series of 1,2-dihydro-1-[(5-methyl-1-imidazol-4-yl)methyl]-2-oxopyridine 5-HT3 antagonists are described. The key pharmacophoric elements were defined as a basic nitrogen, a group capable of hydrogen bonding interactions, and an aromatic moiety. 1,2-Dihydro-2-oxopyridine moiety could be a good linking group because of its nicely planar structure. The steric limitations of the aromatic moiety were investigated by X-ray analysis and computer analysis and shown to be optimal when the aromatic moiety was constrained within an arched planar system, which could be successfully replaced by 3-(2-thienyl)-2-oxopyridine function or 6-amino-7-chloro-1-isoquinolinone function without any loss of the activity. Among the synthesized compounds, 42 showed the most potent activity in the inhibition of Bezold-Jarisch reflex in rats. Compounds 44a and 64 were orally active in the protection against cisplatin-induced emesis in dogs or ferrets. Structure-activity relationships are discussed.
• US8809326B2
  申请人：——

  公开号：US8809326B2

  公开（公告）日：2014-08-19
• [EN] RHO KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA RHO-KINASE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2008036540A2

  公开（公告）日：2008-03-27

  [EN] Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
  [FR] L'invention concerne de nouveaux dérivés de 2H-isoquinolin-1-one et 3H-quinazolin-4-one substitués, utiles en tant qu'inhibiteurs de la rho-kinase ainsi que pour traiter divers troubles et maladies dont la médiation ou le prolongement est assuré par l'activité de la rho-kinase, y compris des maladies cardiovasculaires. L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés pour utiliser de tels composés et des processus pour fabriquer de tels composés.